Healthcare Industry News: bladder cancer
News Release - April 11, 2007
Polymedco Introduces Point of Care Test for Recurrent Bladder Cancer DetectionBTA stat(R) Test Detects Bladder Tumor Associated Antigen in Urine
CORTLANDT MANOR, N.Y., April 11 (HSMN NewsFeed) -- Polymedco, Inc. is pleased to announce the introduction of the BTA statŪ test -- a point of care technology for the early detection of recurrent bladder cancer. This method uses monoclonal antibodies to detect the presence of bladder tumor associated antigen in urine. It is a single-step, rapid immunochromatographic assay for bladder tumor-associated antigen in voided urine. The specificity of the BTA statŪ test was 93-95% in patients with non-genitourinary diseases and cancers and healthy individuals tested as part of a multi-center study. The test has a sensitivity that is considerably higher than voided urine cytology, enabling detection of recurrent early stage and grade cancers that cytology often misses. Requiring five drops of urine, the result is delivered in only five minutes. The appearance of a line in the patient window indicates a positive result. The BTA statŪ test requires one voided urine sample with no sample preparation.
bladder cancer is the fourth most common cancer among men and tenth among females. 57,400 people will be diagnosed with the disease in 2007. It has a 5-year survival rate of 94% if caught early and recurs in over 88% of patients within fifteen years, calling for regular testing and lifelong management.
Polymedco, Inc. is one of the leading marketing and distribution companies in the clinical laboratory marketplace. Since the company's inception in 1980, Polymedco has evolved into a highly skilled and successful marketing and sales and manufacturing organization.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.